Hanall Biopharma’s Prostate Cancer Treatment 'Eligard' Surpasses 10 Billion KRW in Cumulative Sales

Hanall Biopharma is strengthening its position in the prostate cancer treatment market, achieving record-breaking sales as of August with Eligard.

Hanall Biopharma's prostate cancer treatment Eligard. Hanall Biopharma

Hanall Biopharma announced on the 24th that its prostate cancer and precocious puberty treatment, Eligard, recorded cumulative sales of 11.4 billion KRW as of August this year. This figure represents an increase of about 6% compared to the same period last year, marking the highest cumulative performance since its launch.

This achievement is attributed not only to the product's competitiveness but also to Hanall Biopharma's effective market response strategy. In addition to offering various dosages and leveraging the product's proven efficacy through U.S. Food and Drug Administration (FDA) approval, Hanall Biopharma has continuously expanded its presence in the domestic prostate cancer treatment market through a specialized sales and marketing organization.

Eligard is a long-acting injectable formulation containing leuprorelin, developed by Tolmar. Since receiving FDA approval in the United States in 2002, it has been actively prescribed in a total of 89 countries, including the United States, Europe, and Australia, earning recognition for its quality, safety, and efficacy.

Tolmar is a global company with over 30 years of expertise in the development and manufacturing of long-acting injectable drugs in urology, oncology, and endocrinology. Through the development of treatments for major diseases such as prostate cancer, precocious puberty, and testosterone deficiency, Tolmar has established a solid presence in the global market.

The core technology of Eligard, the Atrigel Delivery System, is designed to release the drug steadily in the body over several months, enabling long-lasting effects with a single injection. This feature helps reduce the number of hospital visits for patients and caregivers and plays a positive role in improving treatment adherence.

In 2010, Hanall Biopharma signed an exclusive supply agreement with Tolmar for Eligard and has since supplied three dosage forms-one month (7.5 mg), three months (22.5 mg), and six months (45 mg)-to the domestic market as prostate cancer treatments. In 2023, the six-month formulation also received additional approval as a treatment for central precocious puberty (CPP).

Park Sujin, CEO of Hanall Biopharma, stated, "As the number of prostate cancer patients continues to rise, Eligard has established itself as a trusted treatment option for both patients and medical professionals by demonstrating product quality and stable therapeutic effects that meet global standards. Moving forward, we will continue to provide new treatment options to more patients through new product development and portfolio expansion, further solidifying our leading position in the domestic prostate cancer treatment market."

Meanwhile, according to national cancer registration statistics released in December last year, the number of prostate cancer patients in 2022 was 20,754, making it the second most common cancer among men after lung cancer.

This content was produced with the assistance of AI translation services.